Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009587 | 1.00 | PDE8B (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL31037649 | 1.00 | PDE8B (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL1427736 | 0.95 | HSD17B10 (0.46) | PDE8BATMCHEK2HSD17B10SMN1; SMN2 | |
| SCHEMBL1061613 | 0.95 | HSD17B10 (0.46) | PDE8BATMCHEK2HSD17B10SMN1; SMN2 | |
| SCHEMBL86228 | 0.95 | HSD17B10 (0.46) | PDE8BATMCHEK2HSD17B10SMN1; SMN2 | |
| SCHEMBL16012113 | 0.92 | PDE8B (0.46) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL4574708 | 0.89 | ATM (0.42) | PDE8BATMHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL31420888 | 0.89 | ATM (0.42) | PDE8BATMHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL7923096 | 0.89 | ATM (0.42) | PDE8BATMHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL80021 | 0.88 | PDE8B (0.49) | PDE8BATMCHEK2KDM1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-115894447-A | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021035101-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | PDE8B 3884/4885ATM 835/4885CHEK2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.